Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03597529 · ClinicalTrials.gov registry record · Phase 2
CHOCOlate MeLatonin for AdolescenT MigrainE
A Phase 2 study of Migraine, sponsored by Amy Gelfand.
- Completed
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
- 1
- Study location
NCT03597529 is a Phase 2 study of Migraine that has completed, run by Amy Gelfand. The registered enrollment target is 84 participants, below the 357-participant average among 102 other Migraine trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03597529, a Phase 2 study of Migraine, has completed, sponsored by Amy Gelfand.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
- 1
- Study location
Study Summary
Existing treatments for acute migraine are not effective for all children and adolescents, and can cause side effects. Investigator propose a dose-finding study of melatonin for acute migraine treatment in children and adolescents to determine the best dose to bring forward in a future fully-powered efficacy trial.
Conditions Studied
Interventions
- DRUG Melatonin
Study Locations (1)
California
- University of California, San Francisco, (UCSF) - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2017-09-25 |
| Est. Completion | 2019-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03597529
The ClinicalTrials.gov registry entry for NCT03597529 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 357-participant average among 102 other Migraine trials with a reported enrollment target (76% lower). The listed sponsor is Amy Gelfand, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 1 intervention - of which Melatonin is the first listed.
NCT03597529 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03597529 about?
NCT03597529 is a clinical study titled "CHOCOlate MeLatonin for AdolescenT MigrainE". Existing treatments for acute migraine are not effective for all children and adolescents, and can cause side effects. Investigator propose a dose-finding study of melatonin for acute migraine treatment in children and adolescents to determine the best dose to bring forward in a future fully-powered...
What is the current status of trial NCT03597529?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2017-09-25. Estimated completion is 2019-12-01.
What conditions does trial NCT03597529 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT03597529?
The interventions under investigation include: Melatonin (DRUG).
Who is sponsoring clinical trial NCT03597529?
This trial is sponsored by Amy Gelfand, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03597529 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Migraine Manager (R01)
RECRUITING · Phase 2
-
Bilateral Middle Meningeal Artery Lidocaine Infusion for Chronic Debilitating Migraines
RECRUITING · Phase 2
-
Clinical Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) for the Treatment of Craniofacial Pain
RECRUITING · Phase 2
-
A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine
RECRUITING · Phase 2
-
A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments
ACTIVE NOT RECRUITING · Phase 2
-
Safety and Efficacy Trial of MTX101 2mg for the Acute Treatment of Migraine in Adults
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.